



News Release

DP Clinical-Supported Study Results in FDA Approval of ADMA Biologics' ASCENIV™

ROCKVILLE, MD – September 18, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; congratulates ADMA Biologics' on the approval of ASCENIV™ (immune globulin intravenous, human – sIra 10% liquid). DP Clinical provided a full complement of CRO services for ADMA Biologics program (formerly referred to as RI-002) indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD) in adults and adolescents. This disease affects approximately 250,000 people in the US. “We are pleased that our partnership with ADMA Biologics has resulted in an FDA approved IVIG product for PIDD patients that will be commercially available later this year,” stated Devinder Poonian, President and CEO of DP Clinical. “As a CRO, we are so very proud when a product we have worked with receives FDA approval – it’s why we work so diligently for our Sponsors,” concluded Ms. Poonian.

About DP Clinical

DP Clinical, Inc. is a privately held Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs. We support pharmaceutical, biotech, and medical device companies in their clinical trial development and execution by providing a full complement of clinical program services including trial management, monitoring, data management, biostatistics, regulatory, safety, and medical writing for commercial, academic, and government Sponsors. For more information, visit the company’s Web site at www.dpclinical.com.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD” or “PI”) and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886 and 9,969,793 related to certain aspects of its products. For more information please visit www.admabiologics.com

###

Press Contact: Mary Lee Keen, Director Marketing
DP Clinical, Inc.
301.279.4618
mkeen@dpclinical.com